Spark Therapeutics Shares Plunged More Than 40% Today, Here’s Why

Spark Therapeutics

On Monday, in early trade, Spark Therapeutics, Inc. (NASDAQ:ONCE) saw its shares plunge more than 40%.

What happened? Well, the decline started after the gene therapy biotech company disclosed data from various trials that are aimed at treating hemophilia treatment. While this might sound like a positive thing, analysts deemed that this treatment is less competitive than some products out there.

Enter Your E-mail Address To Subscribe

* indicates required

In the report, Spark Therapeutics presented data from its trial of the treatment for hemophilia. This trial involved five separate patients. 

Additionally, Spark Therapeutics revealed long-term data from a treatment for hemophilia B that it is currently working on with Pfizer, Inc. (NYSE:PFE)

For 2017, shares of Spark Therapeutics are down 14.7%.

Featured Image: twitter